monoamine oxidase Inhibitors
2 drugsAbout monoamine oxidase
Monoamine oxidase (MAO) is an enzyme family regulating monoamine neurotransmitter levels like serotonin, dopamine, and norepinephrine in the brain and other tissues. These neurotransmitters are vital for physiological functions.
MAO is a drug target because inhibiting it can increase neurotransmitter levels, potentially alleviating symptoms of certain conditions. Currently, there is no genetic evidence data available linking MAO to specific diseases.
MAO is targeted by two FDA-approved small molecule drugs: MULTRYS and TRALEMENT, both from AM REGENT. These drugs are approved for 'other' therapeutic areas.
Top monoamine oxidase Drugs
AM REGENT is the only company with approved drugs targeting MAO.
The market is highly concentrated, indicating potential entry barriers or limited commercial opportunity.
monoamine oxidase Drug Modality Landscape
Modalities
Routes of Administration
monoamine oxidase is druggable by small molecules, though no oral formulations are currently approved.
Explore novel modalities like antibodies or gene therapies to differentiate from existing small molecule MAO inhibitors.
monoamine oxidase Clinical Trials 32 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on monoamine oxidase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 | 100% |
| Phase 2 | 10 | 8 | 0 | 2 | 100% |
| Phase 3 | 8 | 6 | 0 | 2 | 100% |
| Phase 4 | 11 | 8 | 2 | 1 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
monoamine oxidase Drug Approval Timeline (2020 - 2020)
The first drug, MULTRYS, was approved in 2020, and the most recent, TRALEMENT, was also approved in 2020.
Recent approvals suggest renewed interest, but the short approval span may indicate market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 27 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on monoamine oxidase. A trial counts if an approved drug acting on monoamine oxidase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.